Back to catalogue
№ 163 39 filings · 2021-07-29 → 2026-07-23

ELECO PUBLIC LIMITED COMPANY

ELCO
Technology Share price 137p Market cap £113m Overall fit 620 /1000

High-quality vertical SaaS with strong operating leverage, fair valuation and net cash protection — but AI angle is enabling rather than a direct receiver, keeping it out of the top band despite otherwise excellent fit.

Fair value range 140p–185p Mid case · £136m
Absolute upside +20.4% vs current market cap
Conviction 4/5 confidence in undervalued call
Supports the call
  • Clean disclosure with full APM reconciliations and consistent 5-year trajectory
  • Two methodologies (fwd P/E and EV/ARR) converge on similar range
  • Fortress balance sheet: net cash £15.4m, no debt, 158% FCF conversion
Limits the call
  • Forward EPS assumes continued mid-teens organic growth execution
  • AIM small-cap: re-rating timing uncertain even if fundamentals deliver
Methodology

Forward P/E (20-24x FY26E adj EPS) cross-checked with EV/ARR (3-4x)

In one line · bull case

High-margin, net-cash vertical SaaS with 85% recurring revenue, 20%+ organic ARR growth and a portfolio cleanup complete — trading at a reasonable ~20x forward earnings after a de-rating.

In one line · biggest risk

Sustained construction-market weakness or a more AI-native competitor eroding pricing power in Asta Powerproject.

Drivers
AI beneficiary 40 /100
AI-enabled features (AstaGPT, Asta Vision Plus API) augment product but no discrete AI revenue line; efficiency benefit rather than receiver of AI capex.
Operating leverage 75 /100
89.6% gross margin, 85% recurring revenue, largely fixed cost base — incremental subscription drops disproportionately to profit.
Earnings vs expectations 75 /100
Consistent 'ahead of expectations' language in FY23/24/25 finals; no profit warnings; H1 2026 in-line with guidance re-affirmed.
Growth momentum 78 /100
H1 2026 organic ARR +23%, organic revenue +15% — acceleration from FY24 organic 9%.
Moat 60 /100
Asta Powerproject: 12 consecutive years UK PM Software of the Year; 110% NRR; sticky vertical specialisation with switching costs.
Earnings quality 80 /100
Free cash flow 158% of operating profit (2025); clean adjusted-to-statutory bridge; one-off Veeuze impairment now behind.
Management quality 72 /100
Two value-accretive acquisitions (Pemac, Kivue), disciplined Veeuze exit, progressive dividend up 20% annually.
Cyclicality 35 /100
Construction end-market exposure exists but is heavily buffered by 85% recurring, multi-year subscription mix.
Leverage 8 /100
Net cash £15.4m at H1 2026, debt-free, only IFRS-16 lease liabilities.

Eleco plc (ELCO) — Investment Research Note

Executive summary

Eleco is an AIM-listed vertical software business selling project scheduling, estimating, asset/maintenance management, PPM and BIM/visualisation tools into the built environment (Asta Powerproject, Pemac, ShireSystem, BestOutcome, Kivue). Over 2021–2025 the group has completed a SaaS/subscription transition — recurring revenue has moved from ~56% to 85% of turnover, ARR has compounded from £16m (2021) to c.£35.5m (H1 2026) — while adjusted EBITDA has stepped from £5.4m (2022) to £10.2m (2025) with FCF conversion above 150% of operating profit. The single most important point for valuation is that this is a genuinely high-quality small-cap vertical SaaS (net cash, 89% gross margin, 110% NRR, 20%+ organic ARR growth) trading around 20x FY25 adj EPS after a drawdown from 175p to 130p — a full-fat quality software business at a modest valuation.

Fair value estimate

  • Fair value range: 140p – 185p per share (~£117m – £155m market cap)
  • Methodology: forward earnings multiple, cross-checked against EV/ARR.
    • FY25 adj EPS 6.3p, FY26E adj EPS ~7.0–7.8p on ~10–15% adj profit growth off 15–20% organic ARR/revenue tailwind (guided in line with market expectations; H1 2026 organic revenue +15%, organic ARR +23%) 2026-07-23 trading update; 2026-04-28 finals.
    • Applying 20–24x forward adj EPS — appropriate for a debt-free vertical SaaS with 85% recurring revenue but discounted for AIM small-cap illiquidity — gives 140–187p.
    • Cross-check: EV/ARR. Enterprise value at 130p ≈ £80m (£95m mcap less £15.4m net cash). ARR £35.5m → EV/ARR ~2.3x, well below quality-SaaS comparables at 3–5x. At 3x ARR EV = £106m → ~145p; at 4x ARR → ~180p. This corroborates the earnings-multiple range.
  • Comparison to £95.2m market cap: fair-value midpoint ~£135m implies ~25% upside from 130p; range implies +8% to +42% upside.
  • View: undervalued (modestly).

Sector context

  • Sector: Technology / Software (ICB Technology). Sub-vertical: specialist vertical SaaS for the built environment (construction planning, asset/maintenance management, PPM, BIM).
  • Quality profile is above typical AIM tech peers on recurring-revenue mix (85%), gross margin (89.6%), balance sheet (net cash, no debt), and disclosure. Growth profile is in line with best-in-class vertical SaaS (~20% organic ARR).
  • Listed peers: RIB Software (delisted, was a direct competitor in construction PM), Craneware (LSE-listed vertical SaaS, healthcare), GetBusy, Nexus Infrastructure/InfoTrack proxies; wider UK vertical software: Sage, Alfa Financial; US/global comparators include Trimble and Autodesk (much larger, but similar end-market).

Investment thesis (3 bullets)

  1. Genuine recurring-revenue quality at a reasonable multiple. Recurring revenue is 85% of H1 2026 total, ARR £35.5m and growing organically +23%, NRR 110%, gross margin 89.6% — this is a high-quality software P&L trading around 20x FY25 adj earnings after a de-rating (share price fell from 175p in July 2025 to 130p) 2026-07-23 H1 trading update; 2026-04-28 FY25 finals.
  2. Fortress balance sheet enables self-funded M&A and downside protection. Cash £15.4m (H1 2026), debt free, free cash flow £8.2m in 2025 (158% of pre-impairment operating profit). This has funded Pemac (£4.6m, immediately profitable, contributing ~£3m revenue plus €1m PBT) and Kivue (£2.3m) without leverage, with earn-outs aligning vendors 2026-04-28 finals; 2026-02-10 Kivue announcement.
  3. Portfolio cleaner post-Veeuze disposal. Management has exited the loss-making German visualisation unit (Veeuze lost £1.3m PBT on £3.7m revenue in 2025) at zero effective consideration, immediately accretive to organic growth, margins and cash — evidence of disciplined capital allocation 2026-04-10 disposal announcement; 2026-04-28 finals.

Key risks (3 bullets)

  1. Construction-cycle exposure limits growth in downturns. Services revenue (18% of 2025 mix) is discretionary and was called out as under pressure through 2024–2025 due to macro/geopolitics; a construction downturn could compress licence and services growth, and further disposals like Veeuze demonstrate that end-markets can turn structurally against product lines 2025-07-24 H1 trading update; 2026-04-28 finals.
  2. AI angle is enabling, not receiving. The AI narrative (AstaGPT, Asta Vision Plus API layer) is genuine but positioned around augmenting professional users, not a demonstrable revenue uplift line. If competitors ship stronger AI-native construction planning or scheduling, Eleco's incumbency-based pricing power in Asta Powerproject could erode 2026-04-28 CEO Report.
  3. Small size / AIM listing = liquidity and re-rating risk. £95m market cap, AIM-listed, 83.5m shares outstanding. Even a good print may not produce sustained re-rating without institutional coverage; the share price has already been volatile (105p–181p in 12 months) and is subject to small-cap discount market data 2026-07-24; inferred from listing status.

Operating leverage

This is a textbook high-operating-leverage business. Gross margin is 89.6% (2025) versus 88.4% (2022), meaning ~90p of every incremental £1 of software revenue drops to gross profit. The overhead base is largely fixed personnel (over 300 staff, 87 engineers) plus hosting; incremental subscription/SaaS revenue does not require materially more inventory, working capital or headcount. Management explicitly flag "operational gearing" and it is visible in the numbers: 2025 revenue grew 20% while adjusted EBITDA grew 32% and adjusted PBT grew 35% 2026-04-28 finals; 2025-09-16 interims. On a 10–20% revenue beat vs current expectations (an extra £4–8m on the c.£43m FY26 base), assuming 80% incremental gross-profit drop-through and modest overhead flex, ~£3–6m would fall to adjusted EBITDA — a 30–60% uplift to the current ~£10m base, and materially more to adjusted PBT given fixed D&A. Contribution margin on incremental SaaS is realistically 60–70%. Constraints: some overhead scales with international footprint and R&D reinvestment stays at 15% of revenue; but the fundamental structure delivers exactly the "revenue surprise → multiples of profit" that the strategy wants.

Value-trap signals

None material identified. Statutory 2025 EPS fell 60% due to the £2.3m Veeuze impairment, but adjusted metrics grew strongly and cash generation was record. Reasons this is not a trap: (a) organic growth accelerating (H1 2026 organic ARR +23% vs FY24 organic 9%); (b) net cash position increasing, dividend rising 20% annually; (c) NRR 110% (customers expanding, not churning); (d) recent US medical-device customer win for Pemac shows expansion into higher-value verticals; (e) auditor report unqualified. Minor watch item: related-party financing package (€1.5m at ECB+5.85%) provided to buyer of Veeuze — properly disclosed and arm's-length, but worth monitoring.

Earnings vs. expectations

Consistent pattern of beating market expectations across the covered period. FY23 finals: results ahead of consensus. FY24 finals: "ahead of market expectations" on revenue, profit and cash. FY25 finals (April 2026): explicitly "Strong Growth with Revenues, Adjusted Profitability and Cash ahead of Market Expectations." H1 2025 interims: "in line with expectations." H1 2026 trading update and AGM statements: "in line with market expectations." Filings do not routinely quote analyst consensus numerically, but the narrative language is consistently "in line with or ahead of." Pattern: consistent beats or in-line; no evidence of guidance cuts or profit warnings in the 5-year window.

Conviction

Conviction: 4 — high.

Supporting factors: (i) very clean disclosure — full APM reconciliations, segment revenue types, geographic splits and quarterly trading updates; (ii) two independent methodologies (P/E and EV/ARR) converge on a similar fair-value band; (iii) five years of consistent operating trajectory (SaaS transition executed, ARR compounding, cash growing) reduces model uncertainty.

Limiting factors: (i) forward EPS assumes continued execution of subscription mix shift and mid-teens organic growth — reasonable but not guaranteed; (ii) AIM small-cap re-rating potential is inherently harder to time than the fundamentals.

Driver scoring summary

  • AI beneficiary: 40 — AI-enabled vertical SaaS, but not a picks-and-shovels AI receiver; benefits are efficiency in R&D and product features rather than a demonstrable revenue line.
  • Operating leverage: 75 — textbook high-fixed-cost SaaS with 89.6% gross margin, 85% recurring revenue.
  • Earnings surprise: 75 — consistent beats/in-line, no profit warnings.
  • Cyclicality: 35 — some construction exposure but heavily buffered by recurring revenue.
  • Moat: 60 — 12 consecutive years as Best Construction PM Software award winner, high NRR, sticky vertical.
  • Leverage: 8 — net cash £15.4m, debt free.
  • Earnings quality: 80 — high cash conversion, clean adjusted vs statutory bridge, minor Veeuze impairment now behind.
  • Management quality: 72 — value-accretive M&A, disciplined divestment, progressive dividend, candid disclosure.
  • Growth momentum: 78 — organic ARR +23%, organic revenue +15% in H1 2026.

Overall score: 620

Solid fit — high-quality vertical SaaS with genuine operating leverage, fair (not stretched) valuation, and strong downside protection. The main limitation for this specific strategy is the AI-receiver angle: Eleco benefits from AI as a feature but is not directly on the physical or infrastructure AI supply chain. That places it firmly in "strong secondary buy" territory rather than the top band.

Filings consulted · 43

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-07-23Trading Update2026-07-23_9682991_trading-update.md0.85
  2. 2026-06-03Agm Statement And Ytd Fy26 Trading Update2026-06-03_9598368_agm-statement-and-ytd-fy26-trading-update.md0.85
  3. 2026-05-07Annual Report Notice OF Agm And Dividend Date2026-05-07_9557806_annual-report-notice-of-agm-and-dividend-date.md0.95
  4. 2026-04-28Final Results2026-04-28_9540473_final-results.md1.00
  5. 2026-04-10Disposal OF Subsidiary2026-04-10_9515458_disposal-of-subsidiary.md0.75
  6. 2026-02-10Acquisition OF Kivue For 2 3M2026-02-10_9422494_acquisition-of-kivue-for-2-3m.md0.75
  7. 2026-01-27Year End Trading Update2026-01-27_9388037_year-end-trading-update.md0.85
  8. 2025-09-16Interim Results2025-09-16_9109699_interim-results.md0.77
  9. 2025-07-24Trading Update2025-07-24_8996402_trading-update.md0.55
  10. 2025-06-03Agm Statement And Trading Update2025-06-03_8908803_agm-statement-and-trading-update.md0.55
  11. 2025-05-12Annual Report Notice OF Agm And Dividend Date2025-05-12_8872372_annual-report-notice-of-agm-and-dividend-date.md0.62
  12. 2025-05-08Investor Presentation Via Investor Meet Company2025-05-08_8866424_investor-presentation-via-investor-meet-company.md0.46
  13. 2025-05-01Final Results2025-05-01_8855691_final-results.md0.65
  14. 2025-01-28Year End Trading Update2025-01-28_8708298_year-end-trading-update.md0.55
  15. 2025-01-14Acquisition OF Pemac2025-01-14_8686493_acquisition-of-pemac.md0.49
  16. 2024-09-10Half Year Report2024-09-10_8407819_half-year-report.md0.58
  17. 2024-08-21Notice OF Results And Investor Presentation2024-08-21_8376595_notice-of-results-and-investor-presentation.md0.46
  18. 2024-07-25Trading Update2024-07-25_8329654_trading-update.md0.55
  19. 2024-06-04Result OF Agm2024-06-04_8241833_result-of-agm.md0.14
  20. 2024-06-04Agm Statement And Q1 2023 Trading Update2024-06-04_8240027_agm-statement-and-q1-2023-trading-update.md0.38
  21. 2024-05-02Annual Report Notice OF Agm Amp Dividend Date2024-05-02_8171390_annual-report-notice-of-agm-amp-dividend-date.md0.43
  22. 2024-04-23Final Results2024-04-23_8150733_final-results.md0.45
  23. 2024-04-16Acquisition OF Vertical Digital2024-04-16_8138817_acquisition-of-vertical-digital.md0.34
  24. 2024-01-23Year End Trading Update2024-01-23_8001031_year-end-trading-update.md0.38
  25. 2023-09-12Interim Results2023-09-12_7749089_interim-results.md0.41
  26. 2023-08-23Notice OF Results And Investor Presentation2023-08-23_7711872_notice-of-results-and-investor-presentation.md0.32
  27. 2023-07-27Trading Update2023-07-27_7657710_trading-update.md0.38
  28. 2023-06-27Acquisition OF Bestoutcome2023-06-27_7596396_acquisition-of-bestoutcome.md0.19
  29. 2023-05-11Result OF Agm2023-05-11_7523682_result-of-agm.md0.07
  30. 2023-05-11Agm Statement And Trading Update2023-05-11_7521666_agm-statement-and-trading-update.md0.21
  31. 2023-04-14Annual Report Notice OF Agm Amp Dividend Date2023-04-14_7491359_annual-report-notice-of-agm-amp-dividend-date.md0.24
  32. 2023-03-28Final Results2023-03-28_7335714_final-results.md0.25
  33. 2023-02-20Disposal2023-02-20_7485767_disposal.md0.19
  34. 2023-01-24Trading Update2023-01-24_7499666_trading-update.md0.21
  35. 2022-09-13Interim Results2022-09-13_7311919_interim-results.md0.23
  36. 2022-07-27Trading Update2022-07-27_7179636_trading-update.md0.21
  37. 2022-05-25Agm Statement And Trading Update2022-05-25_6977308_agm-statement-and-trading-update.md0.21
  38. 2022-04-14Notice OF Agm Annual Report Dividend Date Change2022-04-14_6945989_notice-of-agm-annual-report-dividend-date-change.md0.24
  39. 2022-03-31Final Results2022-03-31_7140661_final-results.md0.25
  40. 2022-03-21Notice OF Results And Investor Presentation2022-03-21_7002090_notice-of-results-and-investor-presentation.md0.17
  41. 2022-01-25Year End Trading Update2022-01-25_6951119_year-end-trading-update.md0.21
  42. 2021-09-15Interim Results2021-09-15_6827271_interim-results.md0.23
  43. 2021-07-29Trading Update2021-07-29_6783624_trading-update.md0.21

This research note was authored by a large language model after reading 39 regulatory filings published between 2021-07-29 and 2026-07-23. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.